Top

Tvardi

Breakthrough Medicines for Cancer, Chronic Inflammation & Fibrosis

Press Releases

Tvardi Therapeutics Announces Publication Demonstrating TTI-101 as a Therapeutic Option for Treatment-Resistant Breast Cancers

Tvardi Therapeutics (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, announced the publication of preclinical studies establishing that its lead compound, TTI-101, is effective against treatment-resistant breast cancers. The paper, published in Clinical Cancer Research, elucidated the STAT3 pathway as the mechanism of resistance and demonstrated that TTI-101 overcame
Read More

Tvardi Therapeutics names Imran Alibhai Chief Executive Officer

Tvardi Therapeutics Inc. (“Tvardi”), a privately held, clinical-stage biopharmaceutical company focused on the development of STAT3 inhibitors, today announced the appointment of Imran Alibhai, Ph.D. as Chief Executive Officer and a member of the Board of Directors, effective immediately. “After a competitive national search, we are delighted to welcome Dr. Alibhai to Tvardi,” said Ron
Read More

Tvardi’s Scientific Advisory Board Member, Dr. Jim Allison, Wins Nobel

Tvardi is pleased to announce that Jim Allison, Scientific Advisory Board Member of the company, has just won the Nobel Prize.  The Nobel Prize in physiology or medicine was awarded Monday morning, October 1, 2018, to cancer researchers James P. Allison and Tasuku Honjo whose studies led to the development of drugs that unleash the
Read More

Tvardi Announces Series A Financing

Tvardi Therapeutics Inc. (“Tvardi”), a clinical-stage private biopharmaceutical company focused on the development of STAT3 inhibitors, announced today the completion of a $9 million Series A financing round. Series A funding is expected to enable the completion of ongoing Phase 1 studies for Tvardi’s lead compound TTI-101 in solid tumor cancers, and the completion of
Read More